| Record ID | marc_loc_2016/BooksAll.2016.part24.utf8:189304980:1285 |
| Source | Library of Congress |
| Download Link | /show-records/marc_loc_2016/BooksAll.2016.part24.utf8:189304980:1285?format=raw |
LEADER: 01285nam a2200373 a 4500
001 95167645
003 DLC
005 19950810150135.2
008 941229s1994 gw a b 000 0 eng d
010 $a 95167645
020 $a3906752666
035 $a(OCoLC)31819399
040 $aDNLM$cDNLM$dDLC
042 $alccopycat
050 00 $aRC848.H43$bS38 1994
060 00 $aW1$bGE876G Bd.6 1994
060 10 $aWC 536$bS415r 1994
082 00 $a616.3/62301$220
100 1 $aSchwicker, David.
245 10 $aRoferon-A in chronic viral hepatitis :$btreatment, clinical outcomes, cost-effectiveness /$cDavid Schwicker, Kurt Banz.
260 $aBern ;$aNew York :$bP. Lang,$cc1994.
300 $a115 p. :$bill. ;$c24 cm.
440 0 $aGesundheit und Ökonomie ;$vBd. 6
504 $aIncludes bibliographical references (p. 109-115).
650 0 $aHepatitis, Viral.
650 12 $aHepatitis, Viral, Human$xdrug therapy.
650 12 $aHepatitis, Viral, Human$xeconomics.
650 22 $aHepatitis, Chronic Active$xdrug therapy.
650 22 $aHepatitis, Chronic Active$xeconomics.
650 22 $aInterferon Alfa-2a$xtherapeutic use.
650 22 $aInterferon Alfa-2a$xeconomics.
650 22 $aCost-Benefit Analysis.
650 22 $aOutcome Assessment (Health Care)
700 1 $aBanz, Kurt.